Copertina

First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancer

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	See‐Tong Pang, Po‐Hung Lin, Emelie Berglund, Lidi Xu, I‐Hung Shao, Kai‐Jie Yu, Chin‐Hsuan Hsieh, Tzu‐Hsuan Chang, Yu Chen, Wen‐Hui Weng, Cheng‐Keng Chuang
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	BJUI Compass
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Genomic prostate score and treatment selection in favourable intermediate‐risk prostate cancer
di: Eric Margolis, et al.
Pubblicazione: (2025)

Quantification of perineural invasion on prostate biopsy improves risk stratification in biopsy Grade Group 2–3 cancer
di: Yuki Teramoto, et al.
Pubblicazione: (2026)

Oncological outcomes post focal low‐dose‐rate brachytherapy in low‐intermediate risk prostate cancer
di: Mohammadmehdi Adhami, et al.
Pubblicazione: (2026)

Increased risk of bleeding during and after HoLEP in patients with prostate cancer: A multicentre comparative cohort study
di: Angelo Porreca, et al.
Pubblicazione: (2025)

Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer
di: Agnieszka Krzyzanowska, et al.
Pubblicazione: (2024)

Multiparametric‐magnetic resonance imaging (mp‐MRI) of the prostate and Urolift: Identifying artefact size, location and clinical implications
di: Cameron James Parkin, et al.
Pubblicazione: (2024)

Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review
di: Abel Tesfai, et al.
Pubblicazione: (2024)

Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm
di: Alan Priester, et al.
Pubblicazione: (2024)

Influences on androgen deprivation therapy prescribing before surgery in high‐risk prostate cancer
di: Jennifer Dunsmore, et al.
Pubblicazione: (2024)

Haematuria cancer risk score as a predictor of muscle‐invasive bladder cancer
di: Serdar Turan, et al.
Pubblicazione: (2025)

Perioperative antibiotic prophylaxis, prostate size and transperineal prostate biopsy
di: Maxwell Louis Sandberg, et al.
Pubblicazione: (2026)

PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer
di: Nicole Handa, et al.
Pubblicazione: (2025)

Omission of contralateral biopsies in unilateral MRI‐suspicious prostate cancer has minimal impact on clinical risk assessment
di: Stijn M. van den Bosch, et al.
Pubblicazione: (2026)

Evaluating the utility of the HAS‐BLED bleeding‐estimator tool for transurethral resection of prostate
di: Lu Yu Kuo, et al.
Pubblicazione: (2025)

Impact of multiparametric MRI and prostate biopsies on anxiety and quality of life in men with suspected prostate cancer
di: Esther H. J. Hamoen, et al.
Pubblicazione: (2025)

Extended versus limited pelvic lymph node dissection and long‐term outcomes in high‐risk prostate cancer before radiotherapy
di: Georgios Daouacher, et al.
Pubblicazione: (2026)

Does bladder outflow obstruction obfuscate the traditional clinical factors that are used to assess the risk of prostate cancer at rapid‐access diagnostic clinics?
di: Thomas Philip Cahill, et al.
Pubblicazione: (2024)

The carbon footprint of transperineal prostate biopsy
di: Daniel A. Carson, et al.
Pubblicazione: (2025)

Emerging tools for the early detection of prostate cancer
di: Muhammad Haider, et al.
Pubblicazione: (2025)

Quality of English‐ and Spanish‐language online content about prostate cancer genetics: Insights into potential contributors to prostate cancer disparities
di: Sophia M. Abusamra, et al.
Pubblicazione: (2025)

Comparing outcomes of Aquablation versus holmium laser enucleation of prostate in the treatment of benign prostatic hyperplasia: A network meta‐analysis
di: Ansh Bhatia, et al.
Pubblicazione: (2024)

Bibliometric analysis of focal therapy in prostate cancer research
di: Mohammed Shahait, et al.
Pubblicazione: (2024)

‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer
di: Ryan Sutherland, et al.
Pubblicazione: (2024)

Micro‐ultrasound tissue echogenicity predicts prostate cancer grade
di: Ailene E. Corona, et al.
Pubblicazione: (2026)

The impact of vaporization on adenoma weight in benign prostatic hyperplasia surgery
di: André B. Silva, et al.
Pubblicazione: (2026)

Long non‐coding RNAs define favourable biology in high‐risk non‐muscle‐invasive bladder cancer
di: Rachel Weng, et al.
Pubblicazione: (2025)

Targeting genomic receptors in voided urine for confirmation of benign prostatic hyperplasia
di: Mathew Thakur, et al.
Pubblicazione: (2024)

Utility of dynamic contrast enhancement for clinically significant prostate cancer detection
di: Eric V. Li, et al.
Pubblicazione: (2024)

National survey of urologists' views on prostate cancer screening in the United Kingdom
di: Nikhil Mayor, et al.
Pubblicazione: (2026)

Focal therapy in prostate cancer: Development, application and outcomes in the United Kingdom
di: Nadia Rokan, et al.
Pubblicazione: (2025)

Multidisciplinary meetings for lower urinary tract symptoms and benign prostate hyperplasia
di: Emilien Seizilles de Mazancourt, et al.
Pubblicazione: (2025)

Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer
di: Ruth Pidsley, et al.
Pubblicazione: (2024)

WATER versus WATER II 5‐year update: Comparing Aquablation therapy for benign prostatic hyperplasia in 30–80‐cm3 and 80–150‐cm3 prostates
di: Mohamad Baker Berjaoui, et al.
Pubblicazione: (2024)

Preoperative FAN score predicts survival outcomes after radical cystectomy for bladder cancer
di: Yu Ishizuya, et al.
Pubblicazione: (2026)

The significant costs of prostate cancer management—An analysis from a Caribbean hospital
di: Geneva Pantoja, et al.
Pubblicazione: (2025)

Impact of recreational football in men with prostate cancer undergoing androgen deprivation therapy
di: Sofia Mesquita, et al.
Pubblicazione: (2025)

Risk factors of negative prostate biopsies: A CHAID decision tree analysis
di: Pierre Allainguillaume, et al.
Pubblicazione: (2026)

Does total lesion prostate‐specific membrane antigen (PSMA) activity on 68Ga‐PSMA PET/CT correlate with PSA and prostatectomy histopathological/clinical outcomes in patients with localised primary prostate cancer?
di: Jeremy Cheng, et al.
Pubblicazione: (2025)

Real‐world clinical outcomes of oligometastatic prostate cancer using SBRT: An Australian experience
di: Samantha Shekar, et al.
Pubblicazione: (2025)

Analysis of urinary volatile organic compounds for prostate cancer diagnosis: A systematic review
di: Jonathon Dawson, et al.
Pubblicazione: (2024)